VRAX Virax Biolabs Group Ltd

Nasdaq viraxbiolabs.com


$ 0.51 $ 0.00 (0.31 %)    

Wednesday, 05-Nov-2025 15:59:50 EST
QQQ $ 622.38 $ 4.94 (0.8 %)
DIA $ 473.04 $ 2.23 (0.47 %)
SPY $ 677.28 $ 2.47 (0.37 %)
TLT $ 89.01 $ -0.57 (-0.64 %)
GLD $ 365.20 $ 0.10 (0.03 %)
$ 0.5116
$ 0.52
$ 0.50 x 3,500
$ 0.53 x 99
$ 0.50 - $ 0.52
$ 0.50 - $ 3.20
73,827
na
2.22M
$ 1.08
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 virax-biolabs-completes-patient-recruitment-for-uk-based-multi-centre-clinical-study-evaluating-performance-of-viraximmune-assay-in-detecting-t-cell-dysfunction-in-pais-including-long-covid-ptld-and-mecfs

Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focus...

 virax-biolabs-group-cfo-jason-davis-to-resign-effective-as-of-june-13-2025

-SEC Filing

Core News & Articles

https://www.who.int/news/item/09-06-2025-fourth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-rega...

 virax-biolabs-investigational-diagnostic-tests-has-an-attractive-market-opportunity-analyst-initiates-with-buy-rating

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market oppo...

 hc-wainwright--co-initiates-coverage-on-virax-biolabs-group-with-buy-rating-announces-price-target-of-3

HC Wainwright & Co. analyst Yi Chen initiates coverage on Virax Biolabs Group (NASDAQ:VRAX) with a Buy rating and announ...

Core News & Articles

https://www.manchestereveningnews.co.uk/news/health/new-case-mpox-detected-uk-30876004 A new case of Mpox has been confirmed in...

 virax-biolabs-announces-2025-strategic-priorities-highlighting-clinical-validation-for-viraximmune-and-global-expansion-of-immuneselect

Looking Ahead to 2025In 2025, our key priorities include:Advancing ViraxImmune™ UK and U.S. Clinical Validation Studies: We wil...

Core News & Articles

Companies will further integrate solutions that help utilities accelerate digitalization and tackle critical challenges such as...

Core News & Articles

https://worldhealthorg.shinyapps.io/mpx_global/

Core News & Articles

https://www.reuters.com/world/uk/uk-detects-two-more-cases-new-mpox-variant-2024-11-04/#:~:text=LONDON%2C%20Nov%204%20(Reuters)...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION